Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
US9907768B2 · kind B2 · utility
24Cited by
16References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2017 |
| Grant date | Mar 6, 2018 |
| Priority date | — |
| Expiry date | Jun 12, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.